ABSTRACT
Breast cancer is the most frequently diagnosed cancer in females of the developed world and is gradually becoming the leading cause in the developing world as well. The innate biology of breast cancer is marked by varied presentations, characteristics, response, recurrence and metastatic phenomenon. Even an early stage breast cancer has the potential to recur and/or metastasize after extremely long duration and this possibility should be borne in the clinician's mind.
ABSTRACT
The majority of children with acute lymphoblastic leukemia can be cured with effective modern day therapy. However, more and more long term sequelae including carcinogenic potential of the treatment are being recognised. We report two children who developed acute lymphoblastic leukemia at the age of 4 and 5 years respectively and were successfully treated. They developed meningioma and astrocytoma at 9 and 3 years respectively after completion of therapy. Both were treated surgically and the patient with astrocytoma also received radiotherapy. Both are now free of disease 19 months after diagnosis of second neoplasm.
Subject(s)
Astrocytoma/diagnosis , Brain Neoplasms/diagnosis , Meningeal Neoplasms/diagnosis , Meningioma/diagnosis , Neoplasms, Second Primary/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Radiotherapy/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Astrocytoma/etiology , Astrocytoma/surgery , Brain Neoplasms/etiology , Brain Neoplasms/prevention & control , Brain Neoplasms/surgery , Child, Preschool , Follow-Up Studies , Humans , Male , Meningeal Neoplasms/etiology , Meningeal Neoplasms/surgery , Meningioma/etiology , Meningioma/surgery , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/surgery , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapyABSTRACT
Children diagnosed with rhabdomyosarcoma at the Tata Memorial Hospital during the period January 1986-December 1988 were studied. All were treated with combination chemotherapy incorporating vincristine, Adriamycin, and cyclophosphamide given sequentially in repeated cycles over 18 months, along with local radiotherapy. Of 24 patients, 18 patients had advanced-stage disease at onset. All patients have been followed up for 18 months or more. Of the 11 patients with group III disease, six are in complete remission; of the six patients with group IV disease, two patients are in complete remission. These results are clearly better than those achieved in the past, where surgery was employed as the primary modality of therapy with chemoradiotherapy given only for patients with group IV disease.
Subject(s)
Rhabdomyosarcoma/therapy , Adolescent , Child , Child, Preschool , Combined Modality Therapy , Female , Humans , Male , Remission Induction , Treatment OutcomeABSTRACT
Between 1984-1987, 50 patients with Ewing's sarcoma of the bone were entered on combined modality protocol at Tata Memorial Hospital. Protocol treatment involved induction therapy consisting of 6-week therapy with vincristine, Adriamycin (doxorubicin), and cyclophosphamide (VDC) followed by local radiotherapy 50 Gy to the involved bone. This was followed for six more cycles of VDC. Five patients had metastatic disease at presentation. Seventy-six percent (38/50) of patients had disease either at axial or proximal site. With a median follow-up of 48 months (range 14-87) 21 patients remained alive with disease-free survival of 38.0% +/- 2.5% at 5 years and overall survival of 36.0% +/- 2.6% at 5 years. Twenty-five patients relapsed with five patients developing local failure and four local and distant metastasis. Using Lee-Desu statistical methods, only response to therapy was a significant factor for survival. We conclude that more aggressive therapy with proper selection of local treatment modality including surgery and/or radiotherapy is required to produce more long-term survival in high-risk Ewing's sarcoma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Sarcoma, Ewing/therapy , Actuarial Analysis , Adolescent , Adult , Bone Neoplasms/drug therapy , Bone Neoplasms/radiotherapy , Chemotherapy, Adjuvant , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Male , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/radiotherapy , Survival Analysis , Vincristine/administration & dosageABSTRACT
This is a report on the management of 210 patients with biopsy-proven OS seen at the Tata Memorial Hospital, Bombay, India from January 1985 to December 1988. The treatment administered to these patients reflects the constraints experienced in cancer management by developing nations. The small number of patients who received neoadjuvant chemoradiotherapy showed the highest survival figures of 30% at 5 years. In the context of the developing countries, limitations of affordability of optimum chemotherapy and the lack of adequate monitoring and support facilities warrant modifications in the currently recommended therapy schedule to suit indigenous needs.
Subject(s)
Bone Neoplasms/therapy , Osteosarcoma/therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/epidemiology , Chemotherapy, Adjuvant , Child , Child, Preschool , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Developing Countries , Doxorubicin/administration & dosage , Female , Humans , India/epidemiology , Lung Neoplasms/epidemiology , Lung Neoplasms/secondary , Male , Methotrexate/administration & dosage , Middle Aged , Osteosarcoma/epidemiology , Osteosarcoma/secondary , Retrospective Studies , Survival Rate , Treatment Outcome , Vinblastine/administration & dosageABSTRACT
A retrospective analysis of 328 cases of Hodgkin's Disease (HD) subjected to a staging laparotomy at the Tata Memorial Hospital, Bombay, India, from 1974 to 1986 was undertaken to assess its relevance to our setup. Eighty percent of the patients were from clinical stages (CS) I and II, 38% with lymphocyte predominance (LP), and 41% with mixed cellularity (MC) histologies. Staging laparotomy was positive in 60% cases overall, including 50% from CS IA and IIA, 68% from CS IB and IIB, and 53% and 67%, respectively, from LP and MC histologies. Splenic involvement was seen in 54% cases. Operative complications were encountered in 2% of cases and deaths in two cases only. In view of the high propensity for abdominal spread, only selected CS IA and IIA cases would merit a staging laparotomy within which, nearly 50% cases with a negative yield could be offered radical segmental irradiation alone for cure. The majority of our patients would, however, require combination therapy.
Subject(s)
Hodgkin Disease/pathology , Adolescent , Adult , Aged , Biopsy , Child , Female , Hodgkin Disease/diagnostic imaging , Hodgkin Disease/mortality , Hodgkin Disease/surgery , Humans , Laparotomy , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , Survival Rate , Tomography, X-Ray ComputedABSTRACT
Twenty-seven patients with pure dysgerminoma were seen at the Tata Memorial Hospital, Bombay, between January 1980 and December 1984. Of the 10 patients in stage I, 2 patients underwent a unilateral salpingoophorectomy (USO) and were kept under observation without any adjuvant therapy, while the remaining patients received adjuvant treatment following surgery. All of the 6 patients in stage II and 4 of 7 in stage III had total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO) followed by postoperative radiotherapy. One patient presented in stage IV and 3 patients presented with recurrence after previous definitive treatment undertaken at other institutions. The disease free, as well as the overall survival, at 108 months, for the 24 cases primarily treated at this institution, is 81% and 88% respectively, and, for patients in stages I and II, 100% (Kaplan-Meier estimation). The need for controlled clinical trials to devise optimal therapy in the early clinical stages and use of chemotherapy for advanced stages of this highly curable entity are stressed.
Subject(s)
Dysgerminoma/therapy , Ovarian Neoplasms/therapy , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Dysgerminoma/mortality , Dysgerminoma/pathology , Dysgerminoma/secondary , Female , Humans , Infant , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Predictive Value of Tests , Recurrence , Survival RateABSTRACT
Primary lymphoma of bone (PLB) is an uncommon clinical entity and a rare presentation of non-Hodgkin's lymphoma. At the Tata Memorial Hospital, over a period of 10 years from 1976 to 1985, 39 cases with a diagnosis of PLB were seen. Twenty-seven cases completed the prescribed treatment and were evaluable for treatment response. Eight patients (21%) presented in clinical stage I (E), four patients (10%) in stage II (E), and 27 patients (69%) in stage IV (E). All of the evaluable patients except two were treated with combination chemotherapy, which consisted of cyclophosphamide, vincristine, and prednisolone in 18 patients, and seven patients received Adriamycin in addition. The majority of patients received six courses of chemotherapy extending over 8 to 12 months. External radiotherapy was given to all except one patient, who had surgery as local treatment. Five patients had generalised relapse, one of which had in addition a local relapse. Five were resistant to treatment. Overall and disease-free survival by Kaplan-Meier method at 60 months are 66% and 56%, respectively.
Subject(s)
Bone Neoplasms/therapy , Lymphoma, Non-Hodgkin/therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Child , Child, Preschool , Combined Modality Therapy , Doxorubicin/administration & dosage , Female , Humans , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Neoplasm Staging , Survival RateSubject(s)
Hodgkin Disease/epidemiology , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Female , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , India/epidemiology , Infant , Infant, Newborn , Male , Neoplasm Staging , Randomized Controlled Trials as Topic , Retrospective StudiesABSTRACT
A retrospective study of 399 cases of buccal cancer, presenting to the Tata Memorial Hospital, Bombay, during January to December 1984 was undertaken to define the efficacy of various treatment modalities in different clinical stages. Analysis of treatment technique and response was carried out in 185 cases that completed adequate therapy. Sixty percent of patients with stage I and II disease (21/35) received radiation therapy alone as the primary modality of treatment. Patients (150) with stage III or IV disease received palliative irradiation (57 cases), radical surgery (54 cases), or a combination of both (39 cases). The 2-year disease-free survival (DFS) rates were 48% for radiotherapy and 46% for surgery in the early stages and 5% and 33%, respectively, for advanced stages. Radiotherapy with a modified technique is recommended for the early-stage cancers and preoperative irradiation with adjuvant chemotherapy or hyperthermia for the advanced stages.
Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Mouth Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Mouth Neoplasms/mortality , Mouth Neoplasms/surgery , Retrospective Studies , Survival RateABSTRACT
One hundred fifty patients with nasopharyngeal carcinoma were treated at the Tata Memorial Hospital from January 1980 to December 1984. Lymphoepithelioma was the most common histologic subtype. Advanced disease in stages III and IV was seen in 22.66% and 72% of the patients, respectively. Complete remission was obtained in 80 of 120 patients (66.66%) with radiation alone and in 19 of 30 patients (63.3%) who received preradiation chemotherapy and radiation. Age, sex, and histology did not influence the rate of complete remission. The N0-1 nodal status group had a significantly better response of 81% and 36% survival, as compared with the N2-3 group with a 55% response and 20% survival. Only 30 of those who received radiation alone and 10 of those who received preradiation chemotherapy are disease-free for a median period of 24 months. Twenty-six relapses have occurred within a median period of 12 months. The 5-year actuarial disease-free survival is 13%. This indicates the need for an early diagnosis and combined aggressive treatment to improve survival.